Reinducing Radioiodine-Sensitivity in Radioiodine-Refractory Thyroid Cancer Using Lenvatinib (RESET): Study Protocol for a Single-Center, Open Label Phase II Trial

Reinducing Radioiodine-Sensitivity in Radioiodine-Refractory Thyroid Cancer Using Lenvatinib (RESET): Study Protocol for a Single-Center, Open Label Phase II Trial

<b>Background</b>: Management of patients with radioiodine (RAI)-refractory differentiated thyroid cancer (DTC) is a challenge as I-131 therapy is deemed ineffective while standard-of-care systemic therapy with tyrosine kinase inhibitor (TKI) lenvatinib is associated with frequent toxici...

Full description

Bibliographic Details
Main Authors: Maaike Dotinga, Dennis Vriens, Floris H. P. van Velden, Mette K. Stam, Jan W. T. Heemskerk, Petra Dibbets-Schneider, Martin Pool, Daphne D. D. Rietbergen, Lioe-Fee de Geus-Oei, Ellen Kapiteijn
Format: Article
Language:English
Published: MDPI AG 2022-12-01
Series:Diagnostics
Subjects:
thyroid cancer
I-124 dosimetry
lenvatinib
radioiodine uptake
redifferentiation
radioiodine-refractory DTC
Online Access:https://www.mdpi.com/2075-4418/12/12/3154

Internet

https://www.mdpi.com/2075-4418/12/12/3154

Similar Items